Flavonoids are heterocyclic compounds found in nature which we consume true everyday diet. Antiplatelet therapy has serious side-effects as bleeding in the gastrointestinal tract. Flavonoids exhibit antiaggregatory effect, with not fully enlightened mechanism. Understanding of this mechanism would allow the use of flavonoids as available and innocuous options in antiplatelet therapy. The chromatographic parameters, retention factor RF and the hydrophobic parameter RM were determined as the lipophilic parameters of flavonoids. The RM values were compared to the logarithm of log of coefficient of partition, obtained through program applications. Impedance aggregometry was used to determine the minimum antiaggregating concentration of flavanone and to investigate the enhanced activity of phospholipase C, cyclooxygenase and Ca2+ channel blockers in the presence of flavanones, and the antiaggregatory action of a combination of flavanone, 6-hydroxyphlavone and pinocembrin-7-methylether. Flow cytometry was used to monitor the expression of activated conformation of integrin αIIbβ3 after incubation of platelets with flavanone. The chromatographic parameters of RM ranged from -0.5942 for luteolin to 0.5202 for tectocrysine and chrysine-dimethylether. Strong positive correlation is present for logP derived thru program applications and RM (r 0.66-0.93 p <0.05). Flavanon achieves extremely low minimum antiaggregating concentrations, significantly contributes to the inhibition of phospholipase C enzyme and a slightly less to activity of Ca2+ channel blockers while it doesn’t contribute to the action of cyclooxygenase inhibitor. In combination with other flavonoids, flavanone achieves significant antiaggregating effect. Flavanone decreased the activation of integrin αIIbβ3. Lipophilicity and interaction with phospholipase C, enable the antiaggregatory action of flavonoids. They, as well as minimal antiaggregating concentrations achievable by diet and enhanced action of flavonoid combinations represent the basis for their possible use option in antiplatelet therapy.